New advances in antifungal treatment

References

• Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147–1201.
   PubMedGoogle Scholar
• Richardson MD, Warnock DW. Aspergillosis. In: Fungal Infec-tion Diagnosis and Management. 2nd edn. Oxford: Blackwell Science Ltd., 1997: 113–130.
   Google Scholar
• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123–138.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 1997; 21: 430–435.
   Google Scholar
• Yee GC, Kennedy MS, Deeg HJ, et al. Cyclosporine associated renal dysfunction in marrow transplant recipients. Transplant Proc 1985; 17: 196–201.
   PubMed Web of Science ®Google Scholar
• Anaissie El, Mattiuzzi N, Miller CB, et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 1998; 424 606–611.
   Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal ampho-tericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–771.
   PubMed Web of Science ®Google Scholar
• Hiemenz JVV, Walsh TJ. Lipid formulation of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 (Suppl. 2): 133–144.
   Google Scholar
• Stevens DA, Yee JY. Analysis of compassionate use itracona-zole therapy for invasive aspergillosis by the NIA1D Mycosis Study Group criteria. Arch Intern Med 1997; 157: 1857-1862.
   Google Scholar
• Denning DW, Lee JY, Hostetler J, et al. NIAID Mycosis Study Group multicenter trial of oral itraconazole therapy for inva-sive aspergillosis. Am J Med 1994; 97: 135–144.
   PubMed Web of Science ®Google Scholar
• Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in au-tologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247–252.
   PubMed Web of Science ®Google Scholar
• Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dex-amethasone-induced immunosuppression of antifungal mono-cyte activity against Aspergillus fianigatus hyphae. J Med Vet Mycol 1996; 34: 68–69.
   Google Scholar
• Flavian M, Lupineti MD, Douglas M, et al. Pulmonary resec-tion for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992; 104: 684–687.
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Grit Care Med 1998; 158: 885–890.
   PubMed Web of Science ®Google Scholar
• Schnitzler N, Peltroche-Llacsahuanga H, Bestier N, et al. Effect of melanin and carotenoids of Exophiala (Wangiella) dermati-adis on phagocytosis, oxidative burst, and killing by human neutrophils. Infect Immun 1999; 67: 94–101.
   PubMed Web of Science ®Google Scholar
• Butler MJ, Day AW. Fungal melanins: a review. Can J Micro-biol 1998; 44: 1115–1136.
   Web of Science ®Google Scholar
• Money NP, Howard RJ. Confirmation of a link between fungal pigmentation, turgor pressure, and pathogenicity using a new method of turgor measurement. Fungal Genet Biol 1996; 20: 217–227.
   Web of Science ®Google Scholar
• Wheeler MH, Bell AA. Melanins and their importance in pathogenic fungi. Curr Top Med Mycol 1988; 2: 338–387.
   PubMedGoogle Scholar
• Cody DT II, Neel HB III, Ferreiro JA, Roberts GD. Allergic fungal sinusitis: the Mayo Clinic experience. Laryngoscope 1994; 104: 1074–1079.
   PubMed Web of Science ®Google Scholar
• Nucci M, Akiti T, Silveira F, et al. Fungemia due to Exophiala jeanselmei. Report of 23 cases. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24–27, 1998, San Diego. Washington DC: American Society for Micro-biology, 1998; Abstract J–141.
   Google Scholar
• Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am 1988; 2: 925–938.
   PubMedGoogle Scholar
• McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis and mycology. J Am Acad Dermatol 1983; & 1–16.
   Google Scholar
• Bayles MAH. Chromomycosis. In: Bailliere's Clin Trop Med Commun Dis. London: Bailliere Tindall, 1989; 45–70.
   Google Scholar
• Restrepo A, Gonzales A, Gomez I, Arango M, De Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann NY Acad Sci 1988; 544: 504–516.
   PubMedGoogle Scholar
• Queiroz-Telles FF, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedro-soi. Int J Dermatol 1992; 31: 805–812.
   Google Scholar
• Bolzinger T, Pradinaud R, Sainte-Marie D, Dupont B, Chwet-zoff E. Traitement de quatre cas de chromomycose a Fonsecaea pedrosoi par l'association 5-fluorocytosine-itraconazole. Nouv Derm 1991; 10: 462–466.
   Google Scholar
• Kullavanijaya P, Rojanavanich V. Successful treatment of chro-moblastomycosis due to Fonsecaea pedrosoi by combination of itraconazole and cryotherapy. Int J Dermato11995; 34:804–807.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Purim KS, Boguszweski CL, Afonso FC, Graf H. Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chro-moblastomycosis. Antimicrob Agents Chemother 1997; 40: 899–902.
   Google Scholar
• Esterre P, Inzan CK, Ramarcel, et al. Treatment of chromomy-cosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol 1996; 134 (Suppl. 46): 33–36.
   Google Scholar
• Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987; 9 (Suppl. 1): S57–S63.
   Google Scholar
• Marco F, Pfaller MA, Messer AS, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433–461.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–2961.
   PubMed Web of Science ®Google Scholar
• Wheat J. Histoplasmosis: experience during outbreaks in Indi-anapolis and review of the literature. Medicine 1997; 76: 339–354.
   PubMed Web of Science ®Google Scholar
• Connolly P, Wheat J, Schni7lein-Bick C, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itracona-zole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999; 43: 322–328.
   Google Scholar
• Johnson P, Wheat LJ, Cloud G, et al. A multicenter randomized trial comparing amphotericin B (AmB) and liposomal ampho-tericin B (AmBisome, LAmB) as induction therapy of dissemi-nated histoplasmosis (DH) in AIDS patients. 7th Conference on Retroviruses and Opportunistic Infections, 2000.
   Google Scholar
• Wheat J, Hafner R, Korzun AH, et al. Itraconazole treat-ment of disseminated histoplasmosis in patients with the ac- quired immunodeficiency syndrome. Am J Med 1995; 98: 336–342.
   PubMed Web of Science ®Google Scholar
• Wheat J, Mawhinney S, Hafner R, et al. Treatment of histoplas-mosis with fluconazole in patients with acquired immunodefi-ciency syndrome. Am J Med 1997; 103: 223–232.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Bradsher RW, Kauffman CA, et al. Treatment of blastomycosis with higher doses of fluconazole. Clin Infect Dis 1997; 25: 200–205.
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993; 119: 28–35.
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Potential new antifungal agents. Curr Opin Infect Dis 1997; 10: 449–458.
   Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40–79.
   Google Scholar
• Graybill JR, Bocanegra R, Najvar LK, Luther MF, Loebenberg D. SCH 56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998; 42: 539–542.
   PubMed Web of Science ®Google Scholar
• Law D, Moore CB, Denning DW. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997; 41:2310–2311.
   Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43: 589–591.
   PubMedGoogle Scholar
• Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccid-ioidomycosis. Antimicrob Agents Chemother 1997; 41: 1558–1561.
   PubMed Web of Science ®Google Scholar
• Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41:2326–2332.
   PubMed Web of Science ®Google Scholar
• Bartlett MS, Current WL, Goheen MP, et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996; 40: 1811–1816.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Luther M, Fothergill A, Rinaldi MG. Treatment of murine Candida krusei or Candida glabrata infec-tion with L-743,872. Antimicrob Agents Chemother 1997; 41: 1937–1939.
   Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898–2905.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizo-pus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251–255.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Montalbo EM, et al. Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob Agents Chemother 1998; 42: 151–153.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Bocanegra R, Hector RF, Luther MF. Efficacy of nikkomycin Z in the treatment of murine histoplas-mosis. Antimicrob Agents Chemother 1998; 42: 2371–2374.
   PubMed Web of Science ®Google Scholar
• Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 1990; 34: 587–593.
   Google Scholar
• Clemons KV, Stevens DA. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997; 41: 2026–2028.
   PubMed Web of Science ®Google Scholar